BioSpace News Archive

BIONIK Laboratories Corp . today reported financial results for its first quarter of fiscal year 2022, for the period ended June 30, 2021.

Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today updated a key clinical development milestone and reported its second-quarter 2021 financial results.

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2021 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2021 with the Securities and Exchange Commission.

Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter, ended June 30, 2021, and provided an overview of the Company’s recent corporate developments.

Celsion Corporation today announced financial results for the three and six months ended June 30, 2021, and provided an update on clinical trial.

Viracta Therapeutics, Inc. today announced financial results for the second quarter of 2021 and provided clinical and corporate updates.

Anebulo Pharmaceuticals, Inc. today announced the formation of a Scientific Advisory Board (SAB) to advise on the Company’s clinical development programs and its product pipeline.

Nimbus Therapeutics today announced the extension of its collaboration with Schrödinger, Inc. to discover and design small molecule therapeutics for a number of high-value targets using cutting-edge structure-based drug design approaches.

Aptevo Therapeutics Inc. today reported its financial results and business highlights for the quarter ended June 30, 2021.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) to ALLO-715 for the treatment of multiple myeloma.